Jeffrey Finer, M.D., Ph.D.
Jeff Finer joined Third Rock in 2016 and focuses on drug discovery and development opportunities across our portfolio. His portfolio company roles include:
- Interim chief technology officer of Ambys Medicines
- Interim chief technology officer of Maze Therapeutics
Jeff brings 30 years of research and clinical experience including 18 years of experience leading drug discovery programs, technology development initiatives, preclinical development, and translational medicine. Prior to joining Third Rock, Jeff spent many years in R&D leadership positions at a number of biotechnology companies. From 2011–2016, he was at Theravance, where he served most recently as vice president, research technology. Prior to that, Jeff was vice president, discovery at Five Prime Therapeutics from 2007-2011, and he served as director, drug discovery technologies at Cytokinetics after helping launch the company in 1998. Jeff has focused his career on breakthrough innovations which have included moving several first-in-class drugs into the clinic and developing novel technology platforms which integrate science, instruments, and informatics. He holds several patents and he has published extensively in peer-reviewed journals. Jeff obtained his M.D. and Ph.D. in Biochemistry from Stanford University School of Medicine, and he holds B.S. degrees in Chemistry and Biology from Massachusetts Institute of Technology. He completed residency training in Internal Medicine at Stanford and in Ophthalmology at Massachusetts Eye & Ear Infirmary and Harvard Medical School.
Jeff’s first high-tech job as a teenager was deploying the first database system used at a funeral home before realizing that he then had to populate it with 90 years of data.